172 related articles for article (PubMed ID: 17855189)
1. Biweekly administration of docetaxel and gemcitabine for elderly patients with advanced non-small cell lung cancer: a phase II study.
Syrigos KN; Karapanagiotou E; Charpidou A; Dilana K; Dannos I; Dionellis G; Rigopoulou A; Georgatou N; Roussos C
J Chemother; 2007 Aug; 19(4):438-43. PubMed ID: 17855189
[TBL] [Abstract][Full Text] [Related]
2. Bi-weekly administration of docetaxel and gemcitabine as first-line therapy for non-small cell lung cancer: a phase II study.
Syrigos KN; Dannos I; Dionellis G; Bofos I; Alamara C; Dimakou E; Stratakos G; Papiris S
Anticancer Res; 2005; 25(5):3489-93. PubMed ID: 16101167
[TBL] [Abstract][Full Text] [Related]
3. Docetaxel in combination with gemcitabine plus rhG-CSF support as second-line treatment in non-small cell lung cancer. A multicenter phase II study.
Kakolyris S; Papadakis E; Tsiafaki X; Kalofonos C; Rapti A; Toubis M; Bania E; Kouroussis C; Chainis K; Androulakis N; Agelaki S; Sarra E; Vardakis N; Georgoulias V;
Lung Cancer; 2001 May; 32(2):179-87. PubMed ID: 11325489
[TBL] [Abstract][Full Text] [Related]
4. Dose-finding, pharmacokinetic and phase II study of docetaxel in combination with gemcitabine in patients with inoperable non-small cell lung cancer.
Rebattu P; Quantin X; Ardiet C; Morere JF; Azarian MR; Schuller-Lebeau MP; Pujol JL
Lung Cancer; 2001; 33(2-3):277-87. PubMed ID: 11551423
[TBL] [Abstract][Full Text] [Related]
5. Gemcitabine and docetaxel as second-line chemotherapy for patients with nonsmall cell lung carcinoma who fail prior paclitaxel plus platinum-based regimens.
Kosmas C; Tsavaris N; Vadiaka M; Stavroyianni N; Koutras A; Malamos N; Onyenadum A; Rokana S; Polyzos A; Kalofonos HP
Cancer; 2001 Dec; 92(11):2902-10. PubMed ID: 11753965
[TBL] [Abstract][Full Text] [Related]
6. A phase II study of sequential docetaxel and gemcitabine followed by docetaxel and carboplatin as first-line therapy for non-small cell lung cancer.
Karapanagiotou EM; Charpidou A; Tzannou I; Dilana K; Kotteas E; Tourkantonis I; Kosmas E; Provata A; Syrigos K
Med Oncol; 2008; 25(3):303-8. PubMed ID: 18204976
[TBL] [Abstract][Full Text] [Related]
7. Gemcitabine plus docetaxel as first-line chemotherapy in patients with advanced non-small cell lung cancer: a lung cancer Galician group phase II study.
Casal J; Amenedo M; Mel JR; Antón LM; Rodríguez-López R; López-López R; González-Ageitos A; Castellanos J; Constenla M; Tisaire JL
Cancer Chemother Pharmacol; 2007 Oct; 60(5):725-32. PubMed ID: 17273825
[TBL] [Abstract][Full Text] [Related]
8. Biweekly administration of docetaxel and gemcitabine as adjuvant therapy for stage II and IIIA non-small cell lung cancer: a phase II study.
Syrigos KN; Konstantinou M; Sepsas E; Papamichales G; Loullias A; Belenis I; Skottis I; Charpidou A; Roussos C
Anticancer Res; 2007; 27(4C):2887-92. PubMed ID: 17695466
[TBL] [Abstract][Full Text] [Related]
9. Gemcitabine and vinorelbine followed by weekly docetaxel in patients with advanced non-small-cell lung cancer: a phase II trial of sequential chemotherapy.
Cobo Dols M; Villar Chamorro E; Alés Díaz I; Gil Calle S; Alcalde García J; Gutiérrez Calderón V; Carabantes Ocón F; Montesa Pino A; Bretón García JJ; Benavides Orgaz M
Clin Transl Oncol; 2006 Oct; 8(10):742-9. PubMed ID: 17074673
[TBL] [Abstract][Full Text] [Related]
10. Randomized phase II study comparing weekly docetaxel-cisplatin vs. gemcitabine-cisplatin in elderly or poor performance status patients with advanced non-small cell lung cancer.
Jang J; Kim HK; Cho BC; Lee KH; Yun HJ; Woo IS; Song HS; Ryoo HM; Kim CH; Sun DS; Shin JW
Cancer Chemother Pharmacol; 2017 May; 79(5):873-880. PubMed ID: 28341958
[TBL] [Abstract][Full Text] [Related]
11. A phase II study of days 1 and 8 combination of docetaxel plus gemcitabine for the second-line treatment of patients with advanced non-small-cell lung cancer and good performance status.
Cobo M; Gutiérrez V; Alcaide J; Alés I; Villar E; Gil S; Durán G; Martínez J; Carabantes F; Bretón JJ; Benavides M
Lung Cancer; 2007 May; 56(2):255-62. PubMed ID: 17276537
[TBL] [Abstract][Full Text] [Related]
12. Results of a phase II multicenter trial of weekly docetaxel and gemcitabine as first-line therapy for patients with advanced non-small cell lung cancer.
Neubauer MA; Garfield DH; Kuerfler PR; Raju RN; Lindquist DL; Soo EW; Khan M; Boehm KA; Asmar L;
Lung Cancer; 2005 Jan; 47(1):121-7. PubMed ID: 15603862
[TBL] [Abstract][Full Text] [Related]
13. Docetaxel/gemcitabine or cisplatin/gemcitabine followed by docetaxel in the first-line treatment of patients with metastatic non-small cell lung cancer (NSCLC): results of a multicentre randomized phase II trial.
Binder D; Schweisfurth H; Grah C; Schäper C; Temmesfeld-Wollbrück B; Siebert G; Suttorp N; Beinert T
Cancer Chemother Pharmacol; 2007 Jun; 60(1):143-50. PubMed ID: 17031643
[TBL] [Abstract][Full Text] [Related]
14. Gemcitabine and docetaxel every 2 weeks in advanced non-small cell lung cancer: a phase II study of the Gruppo Oncologico Italia Meridionale.
Galetta D; Gebbia V; Giotta F; Durini E; Romito S; Borsellino N; Cazzato C; Pezzella G; Colucci G
Lung Cancer; 2002 Oct; 38(1):79-84. PubMed ID: 12367797
[TBL] [Abstract][Full Text] [Related]
15. First line chemotherapy with planned sequential administration of gemcitabine followed by docetaxel in elderly advanced non-small-cell lung cancer patients: a multicenter phase II study.
Tibaldi C; Vasile E; Antonuzzo A; Di Marsico R; Fabbri A; Innocenti F; Tartarelli G; Amoroso D; Andreuccetti M; Lo Dico M; Falcone A
Br J Cancer; 2008 Feb; 98(3):558-63. PubMed ID: 18212755
[TBL] [Abstract][Full Text] [Related]
16. Combination second-line chemotherapy with gemcitabine and docetaxel for recurrent non-small-cell lung cancer after platinum-containing chemotherapy: a phase I/II trial.
Niho S; Kubota K; Goto K; Ohmatsu H; Matsumoto T; Kakinuma R; Nishiwaki Y
Cancer Chemother Pharmacol; 2003 Jul; 52(1):19-24. PubMed ID: 12712259
[TBL] [Abstract][Full Text] [Related]
17. Phase III study of immediate compared with delayed docetaxel after front-line therapy with gemcitabine plus carboplatin in advanced non-small-cell lung cancer.
Fidias PM; Dakhil SR; Lyss AP; Loesch DM; Waterhouse DM; Bromund JL; Chen R; Hristova-Kazmierski M; Treat J; Obasaju CK; Marciniak M; Gill J; Schiller JH
J Clin Oncol; 2009 Feb; 27(4):591-8. PubMed ID: 19075278
[TBL] [Abstract][Full Text] [Related]
18. Phase II trial of weekly docetaxel and gemcitabine for previously untreated, advanced non-small cell lung cancer.
Park SH; Hong J; Kim YS; Kim Y; Kyung SY; An CH; Lee SP; Park JW; Jeong SH; Park J; Cho EK; Shin DB; Lee JH
Lung Cancer; 2008 Oct; 62(1):72-7. PubMed ID: 18342982
[TBL] [Abstract][Full Text] [Related]
19. Combination treatment with weekly docetaxel and gemcitabine for advanced non-small-cell lung cancer in elderly patients and patients with poor performance status: results of a Minnie Pearl Cancer Research Network phase II trial.
Hainsworth JD; Erland JB; Barton JH; Thompson DS; Stagg MP; Bradof JE; Twele TW; Greco EA;
Clin Lung Cancer; 2003 Jul; 5(1):33-8. PubMed ID: 14596701
[TBL] [Abstract][Full Text] [Related]
20. Phase I trial of non-cytotoxic suramin as a modulator of docetaxel and gemcitabine therapy in previously treated patients with non-small cell lung cancer.
Lam ET; Au JL; Otterson GA; Guillaume Wientjes M; Chen L; Shen T; Wei Y; Li X; Bekaii-Saab T; Murgo AJ; Jensen RR; Grever M; Villalona-Calero MA
Cancer Chemother Pharmacol; 2010 Nov; 66(6):1019-29. PubMed ID: 20107799
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
